As a research-led healthcare company, we strive to develop medicines where there is high unmet clinical need.

Flagship Brand

Wintermute Biomedical discovered our patented flagship medicine – WT13.

WT13 demonstrates exceptional potential for the treatment of infections and infectious diseases. Some key advantages of WT13 include:

High-efficacy

With greater potency than competing antibiotics, providing more rapid eradication of bacteria for treatment and prevention of spreading.

Excellent safety

With no signs of toxicity, adverse reactions, or skin irritations captured during in-vitro and in-vivo testing.

Broad spectrum

With activity against gram-positive and gram-negative bacteria.

Combats resistance

With zero evidence of resistance development during standardized testing.

Threat

WT13 has demonstrated efficacy for a wide range of diseases and organisms; most of which make up the CDC’s Biggest Threats list

Infectious Organisms

  • ‍Carbapenem-resistant Enterobacteriaceae (CRE)
  • ‍Extended spectrum beta-lactamase producing Enterobacteriaceae (ESBLs)
  • ‍Multidrug-resistant Pseudomonas aeruginosa
  • ‍Methicillin-resistant Staphylococcus aureus (MRSA)
  • ‍Drug-resistant Streptococcus pneumoniae
  • ‍Vancomycin-resistant Staphylococcus aureus (VRSA)
  • ‍Drug-resistant Streptococcus (Groups A and B)
  • ‍MCR-1 (E. coli)
  • Mycobacterium Ulcerans
  • Plus many more!

Flagship Product

WT13 is currently being formulated as a topical lotion for treating skin infections and wounds, including those caused by Methicillin-resistant Staphylococcus aureus MRSA and other drug-resistant bacteria. Skin infections are among the most common diseases worldwide, placing an immense burden on global healthcare. In 2010, skin infection ranked 4th among all diseases for years lost due to disability (YLD). It is estimated that up to 70% of all people will suffer one or more skin diseases during their lifetime. The micro-organism responsible for the majority of skin infections is Staphylococcus aureus, of which over 60% are MRSA strains (known as “golden staph”).

Today

WT13 is in pre-clinical development, and is anticipated to enter clinical trials soon.

Our Promise

Our team won’t rest until this new antibiotic is available to the many patients who desperately need it.